- Conditions
- Metastatic Breast Cancer, Metastatic Colon/Rectum Cancer, Non-squamous Non-small Cell Lung Cancer
- Interventions
- [F-18]RGD-K5
- Drug
- Lead sponsor
- Siemens Molecular Imaging
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 8
- States / cities
- Irvine, California • Los Angeles, California • Newark, New Jersey + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 17,643
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Age-Related Macular Degeneration
- Interventions
- reduced fluence photodynamic therapy with Visudyne, Lucentis
- Drug
- Lead sponsor
- Barnes Retina Institute
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- TAS-102, Bevacizumab
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Solid Tumors, Metastatic Melanoma, Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Esophageal Squamous Cell Carcinoma (ESCC)
- Interventions
- Lomvastomig
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 2
- States / cities
- New York, New York • Houston, Texas
- Conditions
- Smoking, Bipolar Disorder, Depression
- Interventions
- Varenicline
- Drug
- Lead sponsor
- Mark Frye
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Change in Bone Mineral Density, Bone Loss
- Interventions
- drospirenone 4 mg oral tablet or drospirenone 3.5 mg chewable tablet
- Drug
- Lead sponsor
- Insud Pharma
- Industry
- Eligibility
- 14 Years to 45 Years · Female only
- Enrollment
- 1,536 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2028
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Aurora, Colorado • Boynton Beach, Florida + 17 more
- Conditions
- Pediatric Epilepsy
- Interventions
- Depakote Delayed-Release/Depakote Sprinkle, Depakote ER
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Healthy
- Interventions
- TD-1211, TD-1211+ itraconazole
- Drug
- Lead sponsor
- Glycyx Therapeutics
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Bioavailability, Bioequivalence
- Interventions
- TEPEZZA, EDP
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
- Conditions
- Episodic Migraine
- Interventions
- Atogepant, Ubrogepant
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 263 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Oceanside, California + 34 more
- Conditions
- Anemia Associated With Chronic Kidney Disease
- Interventions
- Roxadustat
- Drug
- Lead sponsor
- Kyntra Bio
- Industry
- Eligibility
- 2 Years to 18 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Omaha, Nebraska • New York, New York + 1 more
- Conditions
- Head and Neck Cancer
- Interventions
- Pembrolizumab, Epacadostat, Cetuximab, Cisplatin, Carboplatin, 5-Fluorouracil
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 14
- States / cities
- Anaheim, California • Sacramento, California • Santa Rosa, California + 11 more
- Conditions
- Cystic Fibrosis
- Interventions
- VX-561, Placebo, IVA
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 11 more
- Conditions
- Healthy
- Interventions
- 2x500 mg Metformin (Glumetza), 5 mg Linagliptin/1000 mg Metformin FDC, 5 mg Linagliptin (Tradjenta), 3x500 mg Metformin (Glumetza), 2 x 500 mg Metformin (Glumetza), 5 mg Linagliptin/1000mg Metformin FDC, 2 x 2.5 mg Linagliptin/750 mg Metformin FDC
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Atrial Fibrillation
- Interventions
- Tecadenoson, Esmolol
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Carcinoma, Non-small-Cell Lung
- Interventions
- Amivantamab, Lazertinib, Carboplatin, Pemetrexed, Direct Oral Anticoagulant (DOAC), Low Molecular Weight Heparin (LMWH)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 520 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 26
- States / cities
- La Jolla, California • Orange, California • Stanford, California + 21 more
- Conditions
- Bacterial Infections, Eye Infections
- Interventions
- AzaSite (azithromycin ophthalmic solution), Vigamox (moxifloxacin hydrochloride ophthalmic solution)
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2008
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Cervical Dystonia
- Interventions
- daxibotulinumtoxinA for injection
- Biological
- Lead sponsor
- Revance Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 357 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 37
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Fountain Valley, California + 32 more
- Conditions
- Attention-Deficit/Hyperactivity Disorder
- Interventions
- SPN-812
- Drug
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 38
- States / cities
- Beverly Hills, California • Garden Grove, California • Los Alamitos, California + 33 more
- Conditions
- Fever After Vaccination, Fever, Seizures Fever
- Interventions
- mRNA COVID-19 Vaccine, Routine Childhood Vaccinations
- Biological
- Lead sponsor
- Duke University
- Other
- Eligibility
- 6 Months to 4 Years
- Enrollment
- 347 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 5
- States / cities
- Oakland, California • Atlanta, Georgia • New York, New York + 2 more
- Conditions
- Primary Immunodeficiency
- Interventions
- IGIV-C 10%, IGSC 20%
- Biological
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 2 Years to 75 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 20
- States / cities
- Los Angeles, California • Santa Monica, California • Denver, Colorado + 17 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- EZN-2208
- Drug
- Lead sponsor
- Enzon Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 36
- States / cities
- Sedona, Arizona • Tucson, Arizona • Murrieta, California + 30 more
- Conditions
- Asthma
- Interventions
- ELLIPTA DPI, GSK MDI, AZ MDI
- Device
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 324 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 20
- States / cities
- Huntington Beach, California • Aventura, Florida • Clearwater, Florida + 17 more
- Conditions
- Diabetic Macular Edema
- Interventions
- K8
- Drug
- Lead sponsor
- Michelle Abou-Jaoude
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky